ReviewFrontiers in neurology2019
Neurofilament Light Chain as a Biomarker in Multiple Sclerosis.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05417269 (A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Blood neurofilament light chain as a predictive biomarker for functional outcome of acute ischemic stroke: a systematic review and meta-analysis.Journal of comparative effectiveness research · 2025Pooled it
- Neurofilament light chain levels in neuronal surface antibody-associated autoimmune encephalitis: a systematic review and meta-analysis.Translational psychiatry · 2025Pooled it
- Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.European journal of neurology · 2021Trial
- Neurofilaments: A Promising Diagnostic and Prognostic Biomarker in Multiple Sclerosis.Annals of neurosciences · 2026Review
- Neuronal Calcium Signaling and Cytoskeletal Dynamics in Neurodegeneration.International journal of molecular sciences · 2026Review
- Cognitive and Neuropsychiatric Sequelae After SARS-CoV-2 Infection: A Narrative Review and Exploratory Cross-Sectional Study of Neurofilament Light Chain and GFAP.Brain sciences · 2026Article
- Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression.Communications medicine · 2026Article
- Ameliorative effects of gum Arabic-coated selenium nanoparticles on Cisplatin-induced cerebellar neurotoxicity in rats.Scientific reports · 2026Article
- The Relationship Between Neurofilament Light Chain and B Lymphocyte Chemoattractant and Cognition in Multiple Sclerosis.Noro psikiyatri arsivi · 2026Article
- Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology.Nature communications · 2025Article
- Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.Inflammopharmacology · 2025Review
- The Possible Role of Neurofilament Light Chain as a Serum Biomarker in Anorexia Nervosa: Clinical Implications.Biomolecules · 2025Article
- Neurofilament Light Chains in Serum Predict Post-Transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy.MedComm · 2025Article
- Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice.International journal of molecular sciences · 2025Review
- Maintenance of chronic neuroinflammation in multiple sclerosis via interferon signaling and CD8 T-cell-mediated cytotoxicity.Research square · 2025Article
- The role of selected NKG2DLs such as MICA, MICB and ULBP4 as potential markers in multiple sclerosis.Scientific reports · 2025Article
- NfL as a biomarker in ATTRv amyloidosis: potential and limitations.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Maintenance of chronic neuroinflammation in multiple sclerosis via interferon signaling and CD8 T cell-mediated cytotoxicity.bioRxiv : the preprint server for biology · 2025Article
- Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis.Neurology international · 2025Article
- Do Nitrosative Stress Molecules Hold Promise as Biomarkers for Multiple Sclerosis?International journal of molecular sciences · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.